Cellectar Biosciences, Inc

(NASDAQ:CLRB)

Latest On Cellectar Biosciences, Inc (CLRB):

Date/Time Type Description Signal Details
2023-05-04 10:28 ESTNewsCellectar Biosciences GAAP EPS of -$0.76N/A
2023-03-09 14:38 ESTNewsCellectar Biosciences GAAP EPS of -$4.05 misses by $0.74N/A
2022-11-04 00:52 ESTNewsCellectar Biosciences GAAP EPS of -$1.28 misses by $0.04N/A
2022-10-21 21:33 ESTNewsCellectar Biosciences shares dip on $10.7M securities offeringN/A
2022-08-05 16:19 ESTNewsCellectar Biosciences GAAP EPS of -$1.22 misses by $0.19N/A
2022-07-22 13:35 ESTNewsCellectar announces reverse stock splitN/A
2022-05-11 01:44 ESTNewsCellectar Biosciences GAAP EPS of -$0.10 in-lineN/A
2022-04-26 10:16 ESTNewsCellectar says committee recommends continuing trial of iopofosine in Waldenstrom’s patientsN/A
2022-03-21 09:50 ESTNewsCellectar Biosciences GAAP EPS of -$0.43 beats by $0.01N/A
2022-02-23 14:23 ESTNewsCellectar Biosciences appoints Chad Kolean as CFO, Jarrod Longcor as COON/A
2021-11-08 09:32 ESTNewsCellectar Biosciences EPS beats by $0.01N/A
2021-11-02 13:51 ESTNewsWarning: CLRB is at high risk of performing badlyN/A
2021-11-02 13:51 ESTNewsCellectar appoints interim chief medical officerN/A
2021-10-25 15:06 ESTNewsCellectar collaborates with BBK Worldwide for concierge service for patients in trialsN/A
2021-08-19 03:37 ESTNewsCellectar awarded $2M phase II NIH SBIR grant to support pivotal study of iopofosine I-131N/A
2021-08-16 15:24 ESTNewsCellectar inks manufacturing and supply agreement with Evergreen for iopofosine I-131N/A
2021-08-10 01:09 ESTNewsCellectar Biosciences EPS in-lineN/A
2021-07-21 00:49 ESTNewsCellectar shares fall after mid-stage CLR 131 trial dataN/A
2021-07-21 00:13 ESTNewsCellectar inks development and commercialization agreement with LegoChemBioN/A
2021-07-21 00:13 ESTNewsCellectar Biosciences inks collaboration agreement with South Korea's LegoChemBioN/A
2021-07-21 00:11 ESTNewsCellectar expands ongoing collaboration agreement with IntoCellN/A
2021-04-27 14:13 ESTNewsCellectar gets notification of formal grant from Australian and Mexican patent authoritiesN/A
2021-03-12 22:14 ESTNewsCellectar Biosciences (CLRB) Investor Presentation - SlideshowN/A
2021-03-04 07:21 ESTFinancialsCompany financials have been released.Neutral
2021-03-03 07:26 ESTEarnings EstimateAn EPS average of -$0.54 is estimated for the 2022 year.Sell
2021-03-03 07:26 ESTEarnings EstimateAn EPS average of -$0.11 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-02 09:56 ESTNewsCellectar Biosciences shares rise after FY resultsN/A
2021-02-20 00:51 ESTNewsInterest in Cellectar increases with private equity purchasesN/A
2021-01-27 13:16 ESTNewsCellectar's CLR 131 an Orphan Drug in European for rare blood cancerN/A
2021-01-13 03:21 ESTAnalyst RatingThe Analyst Target Price has increased from $5.65 to $5.98.Buy
2021-01-12 21:22 ESTNewsCellectar commences pivotal trial of CLR 131 in a rare form bone marrow cancerN/A
2020-12-29 03:24 ESTAnalyst RatingThe Analyst Target Price has increased from $5.57 to $5.65.Buy
2020-12-24 03:50 ESTNewsWATT, MVIS, SOL and ONTX among midday moversN/A
2020-12-23 10:57 ESTNewsCellectar Bio readies stock offeringN/A
2020-12-23 10:57 ESTNewsCellectar Biosciences stock slumps 35% PM, prices public offering and private placementN/A
2020-12-13 03:35 ESTFinancialsCompany financials have been released.Neutral
2020-11-12 11:24 ESTFinancialsCompany financials have been released.Neutral
2020-11-10 11:33 ESTEarnings EstimateAn EPS average of -$0.22 is estimated for the quarter ending on March 31, 2021.Sell
2020-11-07 15:25 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 04:48 ESTNewsCellectar Bio's lead asset shows encouraging action in early-stage pediatric tumor studyN/A
2020-11-01 17:32 ESTFinancialsCompany financials have been released.Neutral
2020-09-19 08:36 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 04:27 ESTFinancialsCompany financials have been released.Neutral
2020-09-15 10:41 ESTNewsCellectar Biosciences Phase 2 Data In Multiple Myeloma Is Worth A LookN/A
2020-09-09 15:39 ESTNewsCellectar's lead asset shows 40% response rate in multiple myeloma studyN/A
2020-08-12 12:12 ESTNewsCellectar Bio files for $100M mixed shelfN/A
2020-08-11 20:28 ESTFinancialsCompany financials have been released.Neutral
2020-08-10 09:11 ESTNewsCellectar Biosciences EPS beats by $0.04N/A
2020-08-06 20:25 ESTFinancialsCompany financials have been released.Neutral
2020-07-31 00:34 ESTFinancialsCompany financials have been released.Neutral

About Cellectar Biosciences, Inc (CLRB):

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) Waldenstrom's macroglobulinemia (WM) and B-cell malignancies; and Phase IIB clinical study in r/r multiple myeloma (MM) patients, as well as Phase I study for various pediatric cancers, R/R head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in preclinical stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; and Orano Med to develop CLR 12120 Series. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

CLRB Quotes by TradingView

See Advanced Chart

General

  • Name Cellectar Biosciences, Inc
  • Symbol CLRB
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 11
  • Last Split Factor1:10
  • Last Split Date2018-07-17
  • Fiscal Year EndDecember
  • IPO Date2005-11-10
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.cellectar.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 6.06
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.44
  • Next Year EPS Estimate -$0.48
  • Next Quarter EPS Estimate -$0.13
  • Return on Assets -27%
  • Return on Equity -47%
  • Earnings Per Share -$3.13
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 96.97 million
  • EBITDA -12093583
  • Analyst Target Price $5.98
  • Book Value Per Share $0.77
View More

Share Statistics

  • Shares Outstanding 50.5 million
  • Shares Float 40.7 million
  • % Held by Insiders 1366%
  • % Held by Institutions 24.14%
  • Shares Short 2.37 million
  • Shares Short Prior Month 2.31 million
  • Short Ratio 0.85
  • Short % of Float 5%
  • Short % of Shares Outstanding 5%
View More

Technicals

  • Beta 1.59
  • 52 Week High $2.98
  • 52 Week Low $1.01
  • 50 Day Moving Average 2.07
  • 200 Day Moving Average 1.66
View More

Dividends

  • Dividend Date 2018-07-17
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Cellectar Biosciences, Inc (CLRB) Dividend Calendar:

CLRB's last dividend payment was made to shareholders on July 17, 2018.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Cellectar Biosciences, Inc (CLRB) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-02$N/A-$0.07-$0.1549.24%
2020-09-302020-11-09$N/A-$0.15-$0.2025%
2020-06-302020-08-10$N/A-$0.26-$0.3012.16%
2020-03-312020-05-07$N/A-$0.42-$0.35-21.14%
2019-12-312020-03-09$N/A-$0.33-$0.379.59%
2019-09-302019-11-12$N/A-$0.42-$0.38-10.53%
2019-06-302019-08-12$N/A-$0.46-$0.6023.33%
2019-03-312019-05-06$N/A-$0.76-$0.74-2.7%
2018-12-312019-02-26$N/A-$0.62-$1.0038%
2018-09-302018-11-13$N/A-$1.65-$0.83-98.8%
2018-06-302018-08-10$N/A-$1.69-$2.1019.52%
2018-03-312018-05-11$N/A-$2.10-$2.00-5%
2017-12-312018-03-21$N/A-$3.40-$2.30-47.83%
2017-09-302017-11-09$N/A-$2.60-$2.50-4%
2017-06-302017-08-14$N/A-$2.30-$2.404.17%
2017-03-312017-05-11$N/A-$2.34-$2.30-1.7%
2016-12-312017-03-15$N/A-$3.40-$2.30-47.83%
2016-09-302016-11-10$N/A-$4.30-$2.00-115%
2016-06-302016-08-11$N/A-$4.90-$4.00-22.5%
2016-03-312016-05-12$N/A$9.10
2015-12-312016-03-11$N/A$11.08
2015-09-302015-11-12$N/A-$24.57
2015-06-302015-08-12$N/A-$30.23
2015-03-312015-05-20$N/A-$30.43
2014-12-312015-03-24$N/A-$34.00
2014-09-302014-11-12$N/A$6.46
2014-06-302014-08-20$N/A-$72.68
2014-03-312014-05-14$N/A-$102.56
2013-12-312014-03-25$N/A-$137.58
2013-09-302013-11-05$N/A-$45.83
2013-06-302013-08-08$N/A-$71.94
2013-03-312013-05-16$N/A-$134.69
2012-12-312013-03-28$N/A-$100.00-$100.000%
2012-09-302012-11-06$N/A-$120.00-$100.00-20%
2012-06-302012-08-09$N/A-$120.00-$120.000%
2012-03-312012-05-14$N/A-$127.71
2011-12-312012-03-09$N/A-$120.00-$100.00-20%
2011-09-302011-11-07$N/A-$142.33
2011-06-302011-08-15$N/A-$201.62
2011-03-312011-05-16$N/A-$682.51
2010-12-312011-03-02$N/A-$31,393.20
2010-09-302010-11-15$N/A-$6,928.17
2010-06-302010-08-14$N/A-$6,802.81
2010-03-312010-05-17$N/A-$6,120.00-$15,300.0060%
2009-12-312010-03-30-$79,560.00-$16,830.00-372.73%
2009-09-302009-11-16-$22,085.86
2009-06-302009-08-06-$39,780.00-$19,890.00-100%
2009-03-312009-05-15-$21,420.00-$27,540.0022.22%
2008-12-312009-03-24-$18,348.62
2008-09-302008-11-12-$21,420.00-$42,840.0050%
2008-06-302008-08-12-$74,777.13
2008-03-312008-05-14-$58,140.00-$39,780.00-46.15%
2007-12-312008-03-24-$55,080.00-$53,550.00-2.86%
2007-09-302007-11-13-$52,020.00-$39,780.00-30.77%
2007-06-302007-08-10-$104,040.00-$36,720.00-183.33%
2007-03-312007-05-30-$19,072.19
2006-12-312007-03-21-$21,420.00-$27,540.0022.22%
2006-09-302006-11-29-$22,351.03
2006-06-302006-08-30-$11,883.56
2006-03-312006-05-31-$13,388.98
2005-12-312006-03-01-$6,116.21
2005-09-302005-11-08-$12,240.00-$12,240.000%
2005-06-302005-08-31-$15,684.32

Cellectar Biosciences, Inc (CLRB) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 2.38 million N/A N/A 2.62 million 2.17 million
Income Before Tax -3.62 million N/A N/A -3.96 million -3.38 million
Selling General Administrative 1.42 million N/A N/A 1.34 million 1.21 million
Gross Profit N/A N/A N/A N/A N/A
Ebit -3.61 million N/A N/A -3.92 million -3.38 million
Operating Income -3.8 million N/A N/A -3.96 million -3.38 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue N/A N/A N/A N/A N/A
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A 4671
Net Income From Continuing Operations -3.62 million N/A N/A -3.96 million -3.38 million
Net Income Applicable to Common Shares -3.62 million -3.91 million -3.61 million -3.96 million -3.38 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A N/A
Change to Liabilities 632277 265646 277522 N/A 347325
Total Cash Flow from Investing Activities N/A -34590 -10553 N/A -3093
Net Borrowings N/A 184000 N/A N/A -568
Total Cash Flow from Financial Activities N/A N/A N/A N/A -568
Change to Operating Activities -393931 151787 -25708 N/A -139938
Change in Cash N/A N/A N/A N/A -3.55 million
Total Cash from Operating Activities -3.5 million -3.05 million -3.51 million N/A -3.54 million
Depreciation N/A N/A N/A N/A 33869
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities -137907 N/A N/A N/A N/A
Change to Net Income 133228 108924 159788 N/A 118193
Capital Expenditures N/A N/A N/A N/A 3093
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 3.86 million N/A N/A 3.44 million 3.19 million
Total Stockholder Equity 54.79 million N/A N/A 5.25 million 7.91 million
Other Current Liabilities 119904 N/A N/A N/A N/A
Total Assets 58.66 million N/A N/A 8.69 million 12.25 million
Common Stock 454 268 254 94 94
Other Current Assets 774432 N/A N/A N/A N/A
Retained Earnings -126.78 million -123.16 million -119.25 million -115.64 million -111.68 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets 81214 219121 81214 81214 81214
Cash 57.17 million N/A N/A 7.09 million 10.61 million
Total Current Liabilities 3.56 million 3.96 million N/A 3.05 million 2.77 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 355982 674679 727541 744899 783924
Total Current Assets 57.94 million 19.8 million N/A 7.86 million 11.39 million
Long Term Investments 75000 N/A N/A N/A N/A
Net Tangible Assets 34.76 million 15.08 million 18.84 million 4.1 million 7.91 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 3.44 million 3.84 million N/A N/A 2.66 million

Cellectar Biosciences, Inc (CLRB) Chart:

Cellectar Biosciences, Inc (CLRB) News:

Below you will find a list of latest news for Cellectar Biosciences, Inc (CLRB) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Cellectar Biosciences, Inc (CLRB) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-172.51.05CALL0 397157.26TRUE00
2024-05-1750.11CALL118 267158.51FALSE-0.05-0.31
2024-05-177.50.09CALL0 270FALSE00
2024-05-172.50.1PUT0 5930FALSE00
2024-05-1752.05PUT1 64156.18TRUE2.050
2024-05-177.50PUT0 0232.75TRUE00
2024-06-212.50CALL0 0633.71TRUE00
2024-06-2150CALL0 00FALSE00
2024-06-217.50CALL0 00FALSE00
2024-06-212.50PUT0 0191.65FALSE00
2024-06-2150PUT0 0146.72TRUE00
2024-06-217.50PUT0 0361.04TRUE00
2024-08-162.51.26CALL0 215135.67TRUE00
2024-08-1650.39CALL0 281136.46FALSE00
2024-08-167.50.55CALL0 250FALSE00
2024-08-162.50.45PUT1 50114.38FALSE0.150.5
2024-08-1652.1PUT1 5793.31TRUE2.10
2024-08-167.50PUT0 0124.77TRUE00
2024-11-152.51.6CALL0 416142.02TRUE00
2024-11-1551CALL0 108126.23FALSE00
2024-11-157.50.7CALL0 220FALSE00
2024-11-152.50.39PUT0 95111.75FALSE00
2024-11-1552.18PUT1 1084.92TRUE2.180
2024-11-157.50PUT0 0108.75TRUE00

Cellectar Biosciences, Inc (CLRB) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920079678/0001104659-20-079678-index.htm
2019-06-07UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1279704/000000000019009604/0000000000-19-009604-index.htm
2020-05-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1279704/000000000020004350/0000000000-20-004350-index.htm
2020-08-18UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1279704/000000000020007592/0000000000-20-007592-index.htm
2020-06-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1279704/000091957420004101/0000919574-20-004101-index.htm
2020-06-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1279704/000093583620000339/0000935836-20-000339-index.htm
2019-06-28SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1279704/000095014219001463/0000950142-19-001463-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1279704/000095014220000330/0000950142-20-000330-index.htm
2019-10-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465919054143/0001104659-19-054143-index.htm
2019-10-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465919054638/0001104659-19-054638-index.htm
2019-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465919057786/0001104659-19-057786-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1279704/000110465919062109/0001104659-19-062109-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465919062134/0001104659-19-062134-index.htm
2019-12-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465919069632/0001104659-19-069632-index.htm
2019-12-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465919070959/0001104659-19-070959-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465919073021/0001104659-19-073021-index.htm
2019-12-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465919074341/0001104659-19-074341-index.htm
2020-01-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920001510/0001104659-20-001510-index.htm
2020-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920001980/0001104659-20-001980-index.htm
2020-01-083Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920002252/0001104659-20-002252-index.htm
2020-01-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920002254/0001104659-20-002254-index.htm
2020-01-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920002668/0001104659-20-002668-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920010608/0001104659-20-010608-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920010610/0001104659-20-010610-index.htm
2020-02-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920010614/0001104659-20-010614-index.htm
2020-02-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920022587/0001104659-20-022587-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920022934/0001104659-20-022934-index.htm
2020-03-054/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920029693/0001104659-20-029693-index.htm
2020-03-054/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920029695/0001104659-20-029695-index.htm
2020-03-054/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920029696/0001104659-20-029696-index.htm
2020-03-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920030739/0001104659-20-030739-index.htm
2020-03-0910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1279704/000110465920030742/0001104659-20-030742-index.htm
2020-04-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920052421/0001104659-20-052421-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920057785/0001104659-20-057785-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1279704/000110465920057790/0001104659-20-057790-index.htm
2020-05-08S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1279704/000110465920058896/0001104659-20-058896-index.htm
2020-05-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920061581/0001104659-20-061581-index.htm
2020-05-20S-1/AGeneral form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1279704/000110465920063931/0001104659-20-063931-index.htm
2020-05-20FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920063977/0001104659-20-063977-index.htm
2020-05-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920065643/0001104659-20-065643-index.htm
2020-06-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920068025/0001104659-20-068025-index.htm
2020-06-01CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1279704/000110465920068212/0001104659-20-068212-index.htm
2020-06-02S-1MEFRegistration adding securities to prior Form S-1 registration [Rule 462(b)]https://www.sec.gov/Archives/edgar/data/1279704/000110465920069148/0001104659-20-069148-index.htm
2020-06-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920069261/0001104659-20-069261-index.htm
2020-06-04424B4Prospectus [Rule 424(b)(4)]https://www.sec.gov/Archives/edgar/data/1279704/000110465920069526/0001104659-20-069526-index.htm
2020-06-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920070345/0001104659-20-070345-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920070837/0001104659-20-070837-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920070839/0001104659-20-070839-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920070840/0001104659-20-070840-index.htm
2020-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920070843/0001104659-20-070843-index.htm
2020-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920072443/0001104659-20-072443-index.htm
2020-06-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920076846/0001104659-20-076846-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920076870/0001104659-20-076870-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920076871/0001104659-20-076871-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920076872/0001104659-20-076872-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920076873/0001104659-20-076873-index.htm
2020-06-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920076875/0001104659-20-076875-index.htm
2020-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920079678/0001104659-20-079678-index.htm
2020-07-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920080838/0001104659-20-080838-index.htm
2020-07-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920080841/0001104659-20-080841-index.htm
2020-07-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1279704/000110465920083048/0001104659-20-083048-index.htm
2020-07-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920085264/0001104659-20-085264-index.htm
2020-08-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920090271/0001104659-20-090271-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920092425/0001104659-20-092425-index.htm
2020-08-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1279704/000110465920092435/0001104659-20-092435-index.htm
2020-08-11S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1279704/000110465920093299/0001104659-20-093299-index.htm
2020-08-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920093312/0001104659-20-093312-index.htm
2020-08-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920096089/0001104659-20-096089-index.htm
2020-08-18CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1279704/000110465920096540/0001104659-20-096540-index.htm
2020-09-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920103944/0001104659-20-103944-index.htm
2020-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000110465920122494/0001104659-20-122494-index.htm
2018-09-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420418050704/0001144204-18-050704-index.htm
2018-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420418051945/0001144204-18-051945-index.htm
2018-10-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420418052128/0001144204-18-052128-index.htm
2018-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420418053874/0001144204-18-053874-index.htm
2018-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420418053875/0001144204-18-053875-index.htm
2018-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420418053876/0001144204-18-053876-index.htm
2018-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420418053877/0001144204-18-053877-index.htm
2018-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420418053878/0001144204-18-053878-index.htm
2018-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420418053879/0001144204-18-053879-index.htm
2018-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420418053880/0001144204-18-053880-index.htm
2018-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420418053881/0001144204-18-053881-index.htm
2018-10-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420418053882/0001144204-18-053882-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420418058877/0001144204-18-058877-index.htm
2018-11-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420418058999/0001144204-18-058999-index.htm
2018-11-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1279704/000114420418059004/0001144204-18-059004-index.htm
2018-11-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420418060503/0001144204-18-060503-index.htm
2018-11-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420418062709/0001144204-18-062709-index.htm
2018-11-304Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420418062710/0001144204-18-062710-index.htm
2018-12-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420418063095/0001144204-18-063095-index.htm
2018-12-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420418064049/0001144204-18-064049-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419000784/0001144204-19-000784-index.htm
2019-01-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419000891/0001144204-19-000891-index.htm
2019-01-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420419002085/0001144204-19-002085-index.htm
2019-01-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420419002088/0001144204-19-002088-index.htm
2019-01-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420419002090/0001144204-19-002090-index.htm
2019-01-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419003300/0001144204-19-003300-index.htm
2019-02-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419008669/0001144204-19-008669-index.htm
2019-02-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419009850/0001144204-19-009850-index.htm
2019-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419009967/0001144204-19-009967-index.htm
2019-02-2610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1279704/000114420419009973/0001144204-19-009973-index.htm
2019-03-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420419011646/0001144204-19-011646-index.htm
2019-03-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419012994/0001144204-19-012994-index.htm
2019-03-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420419013284/0001144204-19-013284-index.htm
2019-03-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419014853/0001144204-19-014853-index.htm
2019-04-17PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1279704/000114420419020076/0001144204-19-020076-index.htm
2019-04-198-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419020345/0001144204-19-020345-index.htm
2019-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1279704/000114420419021924/0001144204-19-021924-index.htm
2019-05-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1279704/000114420419023902/0001144204-19-023902-index.htm
2019-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419023915/0001144204-19-023915-index.htm
2019-05-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419025606/0001144204-19-025606-index.htm
2019-05-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419026601/0001144204-19-026601-index.htm
2019-05-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419026737/0001144204-19-026737-index.htm
2019-05-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1279704/000114420419027124/0001144204-19-027124-index.htm
2019-05-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419027349/0001144204-19-027349-index.htm
2019-05-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419027511/0001144204-19-027511-index.htm
2019-05-31DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420419029286/0001144204-19-029286-index.htm
2019-05-31S-1General form for registration of securities under the Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1279704/000114420419029289/0001144204-19-029289-index.htm
2019-06-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1279704/000114420419030501/0001144204-19-030501-index.htm
2019-06-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419030987/0001144204-19-030987-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420419031006/0001144204-19-031006-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420419031007/0001144204-19-031007-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420419031008/0001144204-19-031008-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420419031009/0001144204-19-031009-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420419031010/0001144204-19-031010-index.htm
2019-07-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419034116/0001144204-19-034116-index.htm
2019-08-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1279704/000114420419039042/0001144204-19-039042-index.htm
2019-08-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419039043/0001144204-19-039043-index.htm
2019-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419040078/0001144204-19-040078-index.htm
2019-08-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419040201/0001144204-19-040201-index.htm
2019-08-26S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1279704/000114420419041667/0001144204-19-041667-index.htm
2019-09-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419043409/0001144204-19-043409-index.htm
2019-09-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419044146/0001144204-19-044146-index.htm
2019-09-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420419044247/0001144204-19-044247-index.htm
2019-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1279704/000114420419044252/0001144204-19-044252-index.htm
2019-09-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419044706/0001144204-19-044706-index.htm
2019-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419045775/0001144204-19-045775-index.htm
2019-09-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419046508/0001144204-19-046508-index.htm
2019-10-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1279704/000114420419047662/0001144204-19-047662-index.htm
2019-02-15SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1279704/000119312519042232/0001193125-19-042232-index.htm
2019-05-28SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1279704/000119312519158290/0001193125-19-158290-index.htm
2019-05-28SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1279704/000119312519158368/0001193125-19-158368-index.htm
2020-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1279704/000119312520030588/0001193125-20-030588-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1279704/000119312520038571/0001193125-20-038571-index.htm
2019-05-24SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1279704/000121390019009528/0001213900-19-009528-index.htm
2020-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1279704/000121390020003189/0001213900-20-003189-index.htm
2019-05-28SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1279704/000121465919003842/0001214659-19-003842-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1279704/000121465920001482/0001214659-20-001482-index.htm
2019-08-2025-NSENotification filed by national security exchange to report the removal from listing and registration of matured, redeemed or rethttps://www.sec.gov/Archives/edgar/data/1279704/000135445719000418/0001354457-19-000418-index.htm
2020-06-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1279704/000138713120005563/0001387131-20-005563-index.htm
2020-07-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1279704/000138713120006297/0001387131-20-006297-index.htm
2019-06-11EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1279704/999999999519001329/9999999995-19-001329-index.htm
2020-06-02EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1279704/999999999520001312/9999999995-20-001312-index.htm
2020-08-20EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1279704/999999999520002217/9999999995-20-002217-index.htm

Cellectar Biosciences, Inc (CLRB) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Cellectar Biosciences, Inc (CLRB). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1366%
Institutional Ownership: 2414%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-11-29STEPHEN A HILLDirectorSell53.002.21117.130.00https://www.sec.gov/Archives/edgar/data/1279704/000114420418062709/0001144204-18-062709-index.htm
2020-02-03Dov ElefantChief Financial OfficerBuy10,000.002.7127,100.0010,000.00https://www.sec.gov/Archives/edgar/data/1279704/000110465920010614/0001104659-20-010614-index.htm
2020-02-03JAMES V CARUSOPresident and CEOBuy100,000.002.71271,000.00100,000.00https://www.sec.gov/Archives/edgar/data/1279704/000110465920010608/0001104659-20-010608-index.htm
2020-06-04STEPHEN A HILLDirectorBuy18,000.001.0819,438.2018,000.00https://www.sec.gov/Archives/edgar/data/1279704/000110465920070843/0001104659-20-070843-index.htm
2018-11-30JAMES V CARUSOPresident and CEOBuy1,000.002.282,282.0022,354.00https://www.sec.gov/Archives/edgar/data/1279704/000114420418062710/0001144204-18-062710-index.htm
2020-02-03Jarrod LongcorChief Business OfficerBuy40,000.002.71108,400.0040,000.00https://www.sec.gov/Archives/edgar/data/1279704/000110465920010610/0001104659-20-010610-index.htm
2020-06-05Dov ElefantChief Financial OfficerBuy4,348.001.154,978.464,348.00https://www.sec.gov/Archives/edgar/data/1279704/000110465920070840/0001104659-20-070840-index.htm
2020-06-05JAMES V CARUSOPresident and CEOBuy21,740.001.1524,892.3044,264.00https://www.sec.gov/Archives/edgar/data/1279704/000110465920070837/0001104659-20-070837-index.htm
2018-11-29STEPHEN A HILLDirectorSell939.002.212,075.2853.00https://www.sec.gov/Archives/edgar/data/1279704/000114420418062709/0001144204-18-062709-index.htm
2020-06-05Jarrod LongcorChief Business OfficerBuy65,218.001.1574,674.6172,518.00https://www.sec.gov/Archives/edgar/data/1279704/000110465920070839/0001104659-20-070839-index.htm
2019-02-28Jarrod LongcorChief Business OfficerBuy100.002.00200.257,300.00https://www.sec.gov/Archives/edgar/data/1279704/000114420419011646/0001144204-19-011646-index.htm